In Healthcare, Who Pays?

Healthcare has no shortage of products that work.

New diagnostics catch disease earlier. Software reduces administrative burden. Remote-care models improve access. Devices make treatment more precise. Many produce real clinical value.

And a surprising number never become meaningful businesses.

The usual explanation is that healthcare is slow to adopt innovation. Sometimes that is true.

More often, the problem is simpler: Nobody has figured out who should pay.

That question sounds less important next to clinical efficacy or technological novelty. It isn’t. In healthcare, it is often the difference between an interesting product and a durable company.

The patient may benefit. The physician may use the product. The health system may have to implement it. The payer may capture the savings.

The economic value is real. It just has an inconvenient habit of showing up somewhere other than where the bill does.

Everyone can agree the product is useful and still conclude that someone else should pay for it.

That is not a sales problem. It is a business-model problem.

Most healthcare businesses eventually depend on one of three economic constituencies: consumers, providers or payers.

Consumers will pay when the value is immediate and personal enough to justify taking out a credit card. Convenience, speed, access, privacy, personalization and peace of mind can all support direct payment. But willingness to pay weakens quickly when the benefit is distant—or when consumers believe insurance should be paying for it instead.

Which, to be fair, they often do.

Providers pay for a different reason. A product has to improve the economics of the practice, health system or care organization. It may create revenue, increase capacity, reduce labor, improve throughput or make an existing service more profitable. Providers are notorious for underinvesting in their businesses. There’s an extraordinarily high bar for a business case.

Payers and risk-bearing organizations have another test. They care about total medical cost, utilization, outcomes and risk. A product that costs money today may be attractive if it prevents a hospitalization six months from now.

The difficulty is that these incentives rarely line up neatly.

A physician may adopt a technology that lowers hospitalization risk but receive none of the savings. A health system may spend money implementing a service that benefits a payer. A payer may hesitate to fund an intervention whose savings will accrue after the member has moved to another plan.

Healthcare is full of these split incentives.

They are one reason clinical value can be necessary and still not be enough.

A company can produce strong outcomes data and still struggle commercially if there is no obvious budget owner. A product can be loved by clinicians and ignored by administrators. A payer can agree that an intervention lowers long-term cost and still decline to reimburse it.

Everyone can be right.

The company can still run out of money.

In other industries, a better product can often create its own demand.

Healthcare is less forgiving.

The commercial model has to be designed with the clinical model.

That means reimbursement, workflow, pricing, contracting and distribution should not be treated as afterthoughts. They are part of the product.

In healthcare, the business model is not simply the wrapper around the innovation. It is part of the innovation.

The strongest healthcare businesses usually make the connection between clinical value and economic value unusually clear.

A technology that saves a physician time is useful. A technology that creates enough capacity for additional patient visits has a clearer economic case.

A diagnostic that identifies risk is clinically interesting. A diagnostic that helps a risk-bearing organization avoid an emergency-room visit or hospitalization is easier to value.

A remote-care service that improves access is attractive. If it also shifts care into a lower-cost setting, the payment logic becomes much stronger.

The shorter the distance between the clinical benefit and the financial benefit, the easier the business is to understand.

This does not mean every healthcare company needs conventional reimbursement.

Some of the most interesting models are emerging outside traditional fee-for-service economics.

Consumers will pay directly for convenience, personalization and access. Employers may fund services that reduce absenteeism or healthcare costs. Value-based care organizations can support interventions that do not fit neatly into a billing code if the total-cost economics work. Pharma and medtech companies may pay for services that improve patient identification, adherence or access.

Hybrid models are becoming more common as well.

A company may combine reimbursement with subscription revenue. A provider may pay for software while a payer funds the clinical intervention it enables. A consumer may pay for a premium layer around a reimbursed service.

The structure can vary. The requirement does not.

Someone needs an economic reason to pay.

This sounds obvious, yet healthcare companies regularly defer the question. The product gets built first. The clinical study comes next. The payment model is expected to work itself out later.

Sometimes it does. Often it doesn’t.

“Reimbursement will catch up” is not a business model. Neither is “payers will eventually recognize the savings.”

Those may be reasonable assumptions. They are still assumptions.

And assumptions, unlike revenue, are remarkably easy to generate.

Investors and strategic buyers increasingly distinguish between healthcare companies with demonstrated demand and those still waiting for the economics to arrive.

That does not mean a company needs a perfect payment model on day one. New categories take time to form. Reimbursement changes. Contracts evolve. Buyers learn.

But there should be a credible path from value created to dollars received.

The best healthcare companies answer three questions at once.

Does it work?

Who benefits enough to pay for it?

Can it fit into the way healthcare is actually delivered?

Clinical innovation answers only the first. The harder work often comes after that.

Healthcare will continue to generate remarkable technologies, diagnostics and care models. Some will change medicine. Many will improve outcomes.

But clinical value alone does not create a business.

Someone still has to pay.